These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 23783394)

  • 1. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
    Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
    Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
    Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
    Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
    Boissel N; Leroy H; Brethon B; Philippe N; de Botton S; Auvrignon A; Raffoux E; Leblanc T; Thomas X; Hermine O; Quesnel B; Baruchel A; Leverger G; Dombret H; Preudhomme C; ;
    Leukemia; 2006 Jun; 20(6):965-70. PubMed ID: 16598313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
    Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
    Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
    Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
    Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
    Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
    Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.
    Wang J; Dao FT; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ; Jiang Q; Qin YZ
    Hematol Oncol; 2022 Oct; 40(4):724-733. PubMed ID: 35531760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
    Paschka P; Du J; Schlenk RF; Gaidzik VI; Bullinger L; Corbacioglu A; Späth D; Kayser S; Schlegelberger B; Krauter J; Ganser A; Köhne CH; Held G; von Lilienfeld-Toal M; Kirchen H; Rummel M; Götze K; Horst HA; Ringhoffer M; Lübbert M; Wattad M; Salih HR; Kündgen A; Döhner H; Döhner K
    Blood; 2013 Jan; 121(1):170-7. PubMed ID: 23115274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
    Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC
    Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.
    Shih LY; Liang DC; Huang CF; Chang YT; Lai CL; Lin TH; Yang CP; Hung IJ; Liu HC; Jaing TH; Wang LY; Yeh TC
    Leukemia; 2008 Feb; 22(2):303-7. PubMed ID: 17960171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
    Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
    Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [C-kit, NPM1 and FLT3 gene mutation patterns and their prognostic significance in 656 Chinese patients with acute myeloid leukemia].
    Ding ZX; Shen HJ; Miao JC; Chen SN; Qiu QC; Qi XF; Jin ZM; Wu DP; He J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):829-34. PubMed ID: 23384905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.
    Santos FP; Jones D; Qiao W; Cortes JE; Ravandi F; Estey EE; Verma D; Kantarjian H; Borthakur G
    Cancer; 2011 May; 117(10):2145-55. PubMed ID: 21523727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.
    Taylor SJ; Thien CB; Dagger SA; Duyvestyn JM; Grove CS; Lee BH; Gilliland DG; Langdon WY
    Exp Hematol; 2015 Mar; 43(3):191-206.e1. PubMed ID: 25534201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NPM1, FLT3, and c-KIT mutations in pediatric acute myeloid leukemia in Russian population.
    Yatsenko Y; Kalennik O; Maschan M; Kalinina I; Maschan A; Nasedkina T
    J Pediatr Hematol Oncol; 2013 Apr; 35(3):e100-8. PubMed ID: 23511494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.